Bagsværd, Denmark, 1 October 2018 ¬- Novo Nordisk today announced plans to make the durable, connected insulin pens NovoPen® 6 and NovoPen Echo® Plus commercially available across key markets commencing in early 2019. In parallel, to support the future integration of its connected pens with broader digital health solutions, Novo Nordisk has signed new partnership agreements with leading diabetes technology companies that share Novo Nordisk's vision to improve the lives of people with diabetes: Dexcom, Glooko and Roche.
The partnerships aim to advance the solutions available for people living with diabetes and their healthcare professionals. Building upon its existing work with IBM Watson Health® and Glooko, Novo Nordisk aims to seamlessly integrate insulin dosing data from connected pen devices with its partners' open ecosystems and diabetes management solutions, such as data from continuous glucose monitoring (CGM) systems and blood glucose meters (BGM).
More details: https://www.novonordisk.com/media/news-details.2218400.html